Liver Fibrosis Assessment in Cases of Chronic Hepatitis C after Direct Acting Antivirals Therapy using Aspartate Aminotransferase to Platelet Ratio Index and Transient Elastograph

Assessment of Degree of Fibrosis in Chronic Hepatitis C Virus Patients Treated with Direct Acting Antiviral Agents

Evaluating the effect of direct-acting agents on liver fibrosis, by real-time elastography, Fibroscan and FIB4 score in chronic HCV patients

Assessment of Changes in Liver Fibrosis and Stiffness, Lipid Profile and Insulin Resistance in Patients with Chronic Hepatitis C Viral Infection Who Received Direct Acting Antivi

ASSESSMENT OF LIVER FIBROSIS BEFORE AND AFTER DIRECT ACTING ANTIVIRAL THERAPY IN COMPENSATED HCV RELATED LIVER DISEASE

Assessment of Fibrosis After Treatment with Direct-Acting Antiviral Drugs with or without Silymarin in Patients with Chronic Hepatitis C Related Liver Disease

Impact of long-term eradication of chronic Hepatitis C infection using the direct-acting antiviral treatment on liver fibrosis parameters in Egyptian patients

Impact of direct-acting antiviral therapy in Egyptian patients with chronic hepatitis C and liver cirrhosis

Non-invasive Evaluation of Liver Fibrosis Changes in Patients with Chronic ‎Hepatitis C after Directly Acting Antiviral Drugs

Effect of DAAs on improvement of liver fibrosis assessed by transiet elastography and associated risk factors for accelerating liver fibrosis